This stock seems to be unique in not having a pre- FDA decision run up. According to data posted here a while ago, stocks with a 2nd submission to the FDA have a 75% success rate. Couple that with the numerous marketing people APPA has hired during the last 6 months--most with experience launching billion dollar oncology drugs-- and today's price becomes even harder to fathom.
sunl, my sentiments exactly! I truly believe this is a "sleeper" and think there has been serious accumulation occurring for months. The absence of increased volume running into Wednesday has me a bit perplexed. After confiding in a seasoned biotech "veteran" friend of mine with substantial and equal shares as I, I am inclined to stay the course.